Metal amount is not metal access

A supplement label describes an input. A blood result samples a circulating pool. A microbiome report describes a community through the assay used to measure it. None, alone, tells us where the metal went, who used it, or whether that use helped the host. The central task is to connect these observations rather than substitute one for another.

Iron makes the distinction concrete: hepcidin can reduce ferroportin-mediated export from cells, restricting delivery to the circulation. Zinc offers a different example: an inflammatory metal-binding protein can disadvantage susceptible microbes while a competitor with effective acquisition machinery retains an advantage. “Less available” always needs an answer to “available to whom?” [1] [2]

Five questions to ask of every metal–microbe claim
QuestionWhat must be specifiedA misleading shortcut
Chemical formIon, oxidation state, ligand, particle, or metal-containing molecule; dissolution and transformation.Treating every compound containing the same element as the same exposure.
Local poolGut lumen, mucosa, blood, tissue, or an intracellular compartment; bound versus exchangeable metal.Calling a low blood value a map of the entire body.
Access machineryTransporters, binding molecules, efflux, host sequestration, and their activity in that setting.Assuming a detected gene is active or every strain has the same capacity.
Biological functionWhat changes: enzyme activity, respiration, competition, barrier function, or immune behavior?Treating a taxonomic shift as the mechanism itself.
Host outcomeAbsorption, cellular use, inflammation, symptoms, and disease course are distinct endpoints.Calling any microbiome change harmful, or any absorption increase therapeutic.

These are linked questions, not a validated equation or risk score. The proposed advance of this atlas is to keep the connections visible—and to mark the ones the evidence has not yet made.

Nutritional immunity has a geography

Host defense does not always mean removing a metal. In a macrophage model, ATP7A-dependent copper trafficking contributed to bacterial killing. In separate work, the bacterial ligand yersiniabactin buffered copper toxicity, and copper–yersiniabactin complexes were detected in human urinary infection samples. Metal delivery and microbial protection can therefore oppose one another. These studies do not constitute a single experiment tracing the same copper pool. [3] [4]

Location can also change the result of the same dietary intervention. In mice, a manganese-rich diet worsened staphylococcal infection in the heart without the same pattern in liver and kidney. Subsequent work implicated altered neutrophil function as well. A story about feeding a bacterium can miss an effect on the cell trying to contain it. [5] [6]

This is why “high” and “low” require a specimen, compartment, method, and comparison. Hypozincemia means low circulating zinc; it does not name zinc status inside every immune cell. A tissue elemental map is not a measurement of its labile, readily exchangeable intracellular pool. The spatial question belongs beside the concentration.

Zinc: better absorption is only one connection

Formulation matters, but the comparison matters just as much. A preliminary crossover study in eight healthy adults estimated greater zinc absorption from aspartate than from gluconate or sulfate when given with milk. It did not test oxide. A different 15-person trial found lower absorption from oxide than from citrate or gluconate under its own conditions. Combining their percentages into an aspartate-versus-oxide ranking would combine different experiments. [7] [8]

Supported in a small human study

Aspartate can change estimated host absorption.

The absorption finding is real within the tested protocol. It is an endpoint about the host. [7]

What is still needed. Direct measurement of the zinc remaining in the gut, its chemical availability, and microbial acquisition before claiming that aspartate bypasses microbes.

Preclinical signal · human mechanism unresolved

Aspartate has a preclinical signal in an MS model.

Oral zinc aspartate improved experimental autoimmune encephalomyelitis in mice. A small human MS trial studied sulfate and depression; it found no between-group difference in the neurological examinations reported. [9] [10]

What is still needed. A human formulation comparison with disease outcomes and evidence that a microbial zinc mechanism mediates any benefit.

Calprotectin fits the question but does not answer it by itself. Its abundance is not a measurement of zinc occupancy, zinc flux, or which organism acquired the withheld metal. Likewise, an MS-associated microbial community does not reveal its zinc economy simply from the species names. Human cohort associations and experimental immune effects provide reasons to investigate, not proof of zinc theft. [2] [11]

Read the zinc comparison, compartment map, and MS evidence ledger

Iron: depleted stores and restricted delivery are different problems

Absolute iron deficiency means stores are depleted. In inflammatory iron restriction, iron may be retained in storage and recycling cells while its delivery for red-cell production is constrained. Both can coexist. These are two mechanisms to distinguish, not an exhaustive classification of anemia. Human inflammatory signaling experiments and cellular ferroportin experiments explain a route from inflammation to reduced circulating iron. [12] [1] [13]

The attractive hypothesis is that oral iron can increase intestinal microbial exposure while host delivery remains limited. That is a question about competing destinations, not proof that every unsuccessful course of ferrous sulfate fed a pathogen. In an IBD trial, oral and intravenous treatment produced different microbial and metabolic changes, while both improved iron deficiency; changes in disease activity were not dependent on route. [14]

Counterevidence must be visible. A South African child trial improved iron status without detecting changes in the measured bacterial groups, short-chain fatty acids, or fecal calprotectin. Its setting and targeted assays matter. The defensible claim is that microbial effects vary with the population, formulation, background ecology, and endpoint—not that replacement is intrinsically harmful. [15]

Read the iron map: depletion, restriction, delivery, and formulation

A disease signature must become a functional question

A list of taxa is the beginning of a hypothesis, not the end of a mechanism. A higher relative abundance can reflect a fall in another population. Species labels do not establish transporter content, expression, access to substrate, or actual metal transfer. Quantitative microbiome profiling in MS shows why bacterial load and confounding can change which associations remain robust. [16]

Chemical selectivity can be very specific: gut bacterial transporters distinguish vitamin B12-related corrinoids. These are cobalt-containing molecules, not interchangeable supplies of free cobalt. Transporter mobility can also change competitive behavior within a gut microbial species. Functional capacity cannot safely be frozen into a permanent “good” or “bad” species label. [17] [18]

The missing links between a signature and an intervention
Evidence layerWhat it contributesWhat remains unproved
Community associationA reproducible association after diet, medication, stool characteristics, and absolute load are considered.That the organisms cause the disease or share one metal-handling phenotype.
Functional potentialGenes and pathways that could acquire, transform, exclude, or redistribute a metal.That they are expressed, chemically supplied, or important in this host.
Activity and fluxEvidence of expression, metabolites, local chemical pools, and movement between compartments.That changing this flux changes the clinical outcome.
Causal and clinical effectAn intervention changes the proposed pathway and a meaningful host endpoint.Whether that pathway mediates the host effect; generalization beyond the tested population, formulation, and setting.

The next useful “signature” would join microbial functions to host regulation and metal chemistry in the same people over time. That is a research objective. This site does not currently possess a validated signature that selects a supplement for an individual.

Make the thesis capable of being wrong

A strong mechanism is not automatically a successful treatment rule. Hepcidin predicted use of oral iron in children, yet a later hepcidin-guided strategy that reduced iron exposure was less effective at improving hemoglobin and failed its prespecified non-inferiority test. Prediction and intervention answer different questions. [19] [20]

A change in the microbiome is also not a clinical endpoint by itself. In one mouse study, oral vitamin B12 changed distal-gut corrinoids and selected bacterial abundances without improving or worsening the measured colitis outcome. Null and discordant results help identify which part of a story actually explains the host. [21]

Use the atlas as a map of connections

Read each profile in two directions: from the chemical form toward the host outcome, and backward from a disease observation toward the measurements needed to explain it. Zinc and iron are the first full worked examples of this approach. Across the broader atlas, distinguish a demonstrated mechanism from a plausible connection and a proposed test.

Follow the metal through four mechanism cases

Browse the complete metals atlas

Choose methods for measuring metals and microbes

Read the evidence guide

Download the framework and linked evidence (JSON)

Contribute a source, counterexample, or correction

Sources & further reading

Primary studies supporting the linked statements. The framework and proposed experiments are editorial synthesis, not a clinical guideline or a systematic review.

  1. Nemeth E et al. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. View source↩↩
  2. Liu JZ, Jellbauer S, Poe AJ, Ton V, Pesciaroli M, Kehl-Fie TE, Restrepo NA, Hosking MP, Edwards RA, Battistoni A, Pasquali P, Lane TE, Chazin WJ, Vogl T, Roth J, Skaar EP, Raffatellu M (2012). Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut. View source↩↩
  3. White C et al. (2009). A role for the ATP7A copper-transporting ATPase in macrophage bactericidal activity. View source↩
  4. Chaturvedi KS et al. (2012). The siderophore yersiniabactin binds copper to protect pathogens during infection. View source↩
  5. Juttukonda LJ et al. (2017). Dietary Manganese Promotes Staphylococcal Infection of the Heart. View source↩
  6. Monteith AJ et al. (2022). Increased Dietary Manganese Impairs Neutrophil Extracellular Trap Formation Rendering Neutrophils Ineffective at Combating Staphylococcus aureus. View source↩
  7. Piacenza F, Giacconi R, Costarelli L, Malavolta M (2023). Preliminary Comparison of Fractional Absorption of Zinc Sulphate, Zinc Gluconate, and Zinc Aspartate after Oral Supplementation in Healthy Human Volunteers. View source↩↩
  8. Wegmüller R, Tay F, Zeder C, Brnic M, Hurrell RF (2014). Zinc absorption by young adults from supplemental zinc citrate is comparable with that from zinc gluconate and higher than from zinc oxide. View source↩
  9. Schubert C, Guttek K, Grüngreiff K, Thielitz A, Bühling F, Reinhold A, Brocke S, Reinhold D (2014). Oral zinc aspartate treats experimental autoimmune encephalomyelitis. View source↩
  10. Salari S, Khomand P, Arasteh M, Yousefzamani B, Hassanzadeh K (2015). Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. View source↩
  11. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. View source↩
  12. Nemeth E et al. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. View source↩
  13. Suominen P et al. (2000). Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anemia. View source↩
  14. Lee T et al. (2017). Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. View source↩
  15. Dostal A et al. (2014). Effects of iron supplementation on dominant bacterial groups in the gut, faecal SCFA and gut inflammation: a randomised, placebo-controlled intervention trial in South African children. View source↩
  16. Pauwels A, Devolder L, Falony G, D'haeseleer M, Nagels G, Van Remoortel A, Derrien M, D'hooghe M, Raes J (2026). Deconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations. View source↩
  17. Degnan PH et al. (2014). Human gut microbes use multiple transporters to distinguish vitamin B₁₂ analogs and compete in the gut. View source↩
  18. Frye KA et al. (2021). Mobilization of vitamin B12 transporters alters competitive dynamics in a human gut microbe. View source↩
  19. Prentice AM et al. (2012). Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. View source↩
  20. Wegmüller R et al. (2023). Hepcidin-guided screen-and-treat interventions for young children with iron-deficiency anaemia in The Gambia: an individually randomised, three-arm, double-blind, controlled, proof-of-concept, non-inferiority trial. View source↩
  21. Kelly CJ et al. (2019). Oral vitamin B12 supplement is delivered to the distal gut, altering the corrinoid profile and selectively depleting Bacteroides in C57BL/6 mice. View source↩